Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are rare, severe cutaneous adverse reactions that result in in‐hospital death in 12–49% of cases. The severity‐of‐illness score for toxic epidermal necrolysis (SCORTEN) is the most widely used mortality prognosis score; however, it has been shown to have critical limitations. Other mortality predictors not incorporated in SCORTEN or other predictor tools are being increasingly reported. This systematic review and meta‐analysis aimed to synthesize and evaluate the predictors of mortality in adults with Stevens‐Johnson syndrome and toxic epidermal necrolysis not included in SCORTEN. It was registered with the International Platform of Registered Systematic Review and Meta‐Analysis Protocols (INPLASY) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) reporting guidelines. Potential bias was assessed using the National Institutes of Health (NIH) criteria. Forty articles describing results from 52,398 cases were included. Sixteen predictors were reported in five or more articles, and thirty‐three were reported in two to four articles. Meta‐analysis showed preexisting renal disease (odds ratio (OR): 3.14, 95% confidence interval (CI): 1.99–4.97, P < 0.0001, I2 = 21%), renal involvement (OR: 5.62, 95% CI: 2.29–13.77, P = 0.0002, I2 = 36%), respiratory involvement (OR: 3.14, 95% CI: 1.25–7.92, P = 0.015, I2 = 66%), diabetes mellitus (OR: 1.87, 95% CI: 1.21–2.89, P = 0.005, I2 = 19%), sepsis (OR: 5.64, 95% CI: 2.81–11.29, P < 0.0001, I2 = 63%), comorbidity (OR: 9.13, 95% CI: 4.60–18.12, P < 0.0001, I2 = 0%), and time to hospitalization (OR: 2.56, 95% CI: 1.15–5.65, P = 0.021, I2 = 93) increased risk of mortality. This systematic review and meta‐analysis support several clinical and laboratory parameters not included in SCORTEN (preexisting renal disease, renal involvement, respiratory involvement, diabetes mellitus, sepsis, comorbidities, and time to hospitalization) as predictors of mortality in adults with SJS/TEN. The future utilization of these factors may improve mortality prognostication in adults with SJS/TEN.
